Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the initiation of a Phase 2A clinical trial for the company’s lead candidate, PTX-100, targeting relapsed or refractory cutaneous T-cell lymphoma (CTCL). This marks a significant milestone as the first patient has now been dosed in the study.
McDonnell explained the extensive groundwork required to reach this stage, including obtaining FDA acceptance of their IND and orphan drug designation. “Everything that goes into getting to this point is enormous,” he said.
PTX-100 differentiates from existing therapies by offering a novel mechanism of action and a favourable safety profile. “A lot of the drugs at the moment have a serious adverse event profile… whereas PTX-100 has a sizable safety profile and good response rates,” McDonnell noted.
The trial will run in multiple countries, which the company says is necessary given the rarity of the disease. Prescient also aims to support global commercialisation efforts. With FDA fast track and orphan drug designation, the company is hoping for a more streamlined development pathway and potential market exclusivity.
Looking ahead, McDonnell said the company remains focused on PTX-100 while exploring further applications in peripheral T-cell lymphoma and potentially other cancers involving Ras pathway disruption.
Watch the full video to hear what’s next for Prescient Therapeutics as it moves through clinical development.
? For more updates like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications so you never miss future content.
#PrescientTherapeutics #PTX100 #TCellLymphoma #BiotechNews #CancerTreatment #ClinicalTrials #OncologyUpdates #FDAFastTrack #OrphanDrug #BiotechInvesting #CancerResearch #RasPathway #CutaneousLymphoma